MissionIR Articles

Cardium Therapeutics has completed the second tranche of its previously announced registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the…

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced a 1-for-20 reverse split of the company’s issued and outstanding common stock, effective today at market open, reducing the number of issued and outstanding…

Cardium Therapeutics focuses on the fields of health sciences and regenerative medicine to carry out its business model of acquiring and developing new and innovative bio-medical product opportunities and businesses with the potential to address…

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, is remarkably well balanced for ongoing growth in the health and therapeutic marketplace. The company has products that cover the range from well-established…

Ask any physician or health care professional what America’s biggest single health problem is and you will likely get an answer that points to cardiovascular disease and the lifestyle issues that promote it, such as…

Cardium Therapeutics has established a diversified portfolio of medical products with large market potential. Armed with a capital-efficient, asset-based business strategy, the company is positioned to continue to build its portfolio with balanced risk/return opportunities…

It’s not something you’d expect to find in a regenerative medicine company’s portfolio, but Cardium Therapeutics’ To Go Brands healthy nutraceutical supplement business is complementary to the company’s overarching mission of meeting unmet medical needs…

When we contemplate the effects that digital electronics has had on health, we are likely to think of the truly amazing progress made in things like medical diagnostics or medical information processing and communication. What…

Today before the opening bell, Cardium Therapeutics announced that Institutional Shareholder Services, Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), the nation’s leading independent proxy advisory firms, each recommend that Cardium’s stockholders vote…

Cardium Therapeutics announced earlier this year that it had arranged a distribution venture with Academy Medical for marketing, sale, and distribution of Excellagen, an FDA-cleared advanced gel with the ability to speed up the healing…

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments. The company narrowed its first-quarter loss to $2.2 million from a net…

As hard as it may seem to believe, the American Diabetes Association says that over 8% of the U.S. population, roughly 1 out of 12 Americans, now has diabetes. That’s nearly 26 million people, though…

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today highlighted the publication, “Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors,” authored by Gabor M Rubanyi,…

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, is scheduled to present a poster demonstrating the clinical benefits of its lead commercial product, Excellagen®, at The Symposium on Advanced Wound Care and Wound…

Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they…

When Cardium Therapeutics recently released their 2012 financial results, reflecting the company’s extensive investment required for the important introduction of Excellagen and nutraceutical initiatives, and the initiation of their Generx ASPIRE clinical study, the standout…

Cardium Therapeutics, a medical technology company focused on cardiovascular and tissue repair, has developed and is implementing a comprehensive commercialization strategy for Excellagen, the company’s novel syringe-based gel to boost the healing process for all…

Today before the opening bell, Cardium made a series of announcements as well as provided a comprehensive update on its ongoing initiatives. An abridged overview is presented below due to the length of the press…

The number and degree of medical advances over the past 50 years is astonishing, offering hope for the afflicted never before possible or even imaginable. But it’s hope that comes with a very steep price.…